Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Buy
62
ZBH Quote, Financials, Valuation and Earnings
Last price:
$112.27
Seasonality move
:
1.2%
Day range:
$111.92 - $113.08
52-week range:
$97.69 - $133.90
Dividend yield:
0.86%
P/E ratio:
25.23x
P/S ratio:
2.98x
P/B ratio:
1.79x
Volume:
1M
Avg. volume:
1.8M
1-year change:
-14.94%
Market cap:
$22.3B
Revenue:
$7.7B
EPS (TTM):
$4.45
Analysts' Opinion
-
Consensus RatingZimmer Biomet Holdings has received a consensus rating of Hold. The company's average rating is a Hold based on 5 Buy ratings, 17 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $122.04, Zimmer Biomet Holdings has an estimated upside of 8.72% from its current price of $112.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $105.00 representing 6.47% downside risk from its current price of $112.26.
Fair Value
-
According to the consensus of 23 analysts, Zimmer Biomet Holdings has 8.72% upside to fair value with a price target of $122.04 per share.
ZBH vs. S&P 500
-
Over the past 5 trading days, Zimmer Biomet Holdings has overperformed the S&P 500 by 2.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Zimmer Biomet Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zimmer Biomet Holdings has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Zimmer Biomet Holdings reported revenues of $2B.
Earnings Growth
-
Zimmer Biomet Holdings earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Zimmer Biomet Holdings reported earnings per share of $1.20.
Enterprise value:
28B
EV / Invested capital:
--
Price / LTM sales:
2.98x
EV / EBIT:
22.35x
EV / Revenue:
3.65x
PEG ratio (5yr expected):
0.15x
EV / Free cash flow:
24.54x
Price / Operating cash flow:
20.03x
Enterprise value / EBITDA:
12.45x
Gross Profit (TTM):
$5.5B
Return On Assets:
4.2%
Net Income Margin (TTM):
11.77%
Return On Equity:
7.21%
Return On Invested Capital:
4.87%
Operating Margin:
20.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $6.9B | $7.4B | $7.7B | $1.9B | $2B | |
| Gross Profit | $4.9B | $5.3B | $5.5B | $1.4B | $1.4B | |
| Operating Income | $1.2B | $1.5B | $1.5B | $420.8M | $423.5M | |
| EBITDA | $1.5B | $2.2B | $2.3B | $576M | $614.5M | |
| Diluted EPS | $1.10 | $4.89 | $4.45 | $2.01 | $1.20 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.1B | $4.9B | $4.4B | $4.6B | $4.7B | |
| Total Assets | $24.4B | $23.5B | $21.1B | $21.5B | $21.4B | |
| Current Liabilities | $2.6B | $3.5B | $2.4B | $2.9B | $2.5B | |
| Total Liabilities | $12.2B | $10.8B | $9B | $9B | $8.9B | |
| Total Equity | $12.2B | $12.7B | $12B | $12.5B | $12.5B | |
| Total Debt | $8.1B | $7.1B | $5.7B | $5.8B | $6.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.3B | $1.6B | $1.5B | $588.4M | $506.3M | |
| Cash From Investing | -$529.2M | -$778.9M | -$888.1M | -$220.8M | -$291.2M | |
| Cash From Financing | -$843.8M | -$763.5M | -$484.5M | -$251.4M | -$240.6M | |
| Free Cash Flow | $1.1B | $1.2B | $1.1B | $520.6M | $421.4M | |
ZBH
Sector
Market Cap
$22.3B
$36.5M
Price % of 52-Week High
83.84%
44.66%
Dividend Yield
0.86%
0%
Shareholder Yield
4.35%
-0.9%
1-Year Price Total Return
-14.94%
-39.9%
Beta (5-Year)
1.037
0.774
Dividend yield:
0.86%
Annualized payout:
$0.96
Payout ratio:
21.69%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$111.51
200-day SMA
Buy
Level
$107.88
Bollinger Bands (100)
Buy
Level
104.27 - 111.05
Chaikin Money Flow
Buy
Level
275.1M
20-day SMA
Buy
Level
$108.87
Relative Strength Index (RSI14)
Buy
Level
60.20
ADX Line
Buy
Level
16.55
Williams %R
Sell
Level
-15.9924
50-day SMA
Buy
Level
$107.23
MACD (12, 26)
Buy
Level
1.73
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
10.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8243)
Buy
CA Score
(Annual)
Level (0.3158)
Buy
Beneish M-Score
(Annual)
Level (-2.594)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-1.6448)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Stock Forecast FAQ
In the current month, ZBH has received 5 Buy ratings 17 Hold ratings, and 1 Sell ratings. The ZBH average analyst price target in the past 3 months is $122.04.
-
Where Will Zimmer Biomet Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zimmer Biomet Holdings share price will rise to $122.04 per share over the next 12 months.
-
What Do Analysts Say About Zimmer Biomet Holdings?
Analysts are divided on their view about Zimmer Biomet Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zimmer Biomet Holdings is a Sell and believe this share price will drop from its current level to $105.00.
-
What Is Zimmer Biomet Holdings's Price Target?
The price target for Zimmer Biomet Holdings over the next 1-year time period is forecast to be $122.04 according to 23 Wall Street analysts, 5 of them rate the stock a Buy, 1 rates the stock a Sell, and 17 analysts rate the stock a Hold.
-
Is ZBH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zimmer Biomet Holdings is a Hold. 17 of 23 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ZBH?
You can purchase shares of Zimmer Biomet Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zimmer Biomet Holdings shares.
-
What Is The Zimmer Biomet Holdings Share Price Today?
Zimmer Biomet Holdings was last trading at $112.27 per share. This represents the most recent stock quote for Zimmer Biomet Holdings. Yesterday, Zimmer Biomet Holdings closed at $112.26 per share.
-
How To Buy Zimmer Biomet Holdings Stock Online?
In order to purchase Zimmer Biomet Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
